Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09JSM
|
|||
| Former ID |
DNCL002198
|
|||
| Drug Name |
IMC-3C5
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vascular endothelial growth factor receptor 3 (FLT-4) | Target Info | Modulator | [2] |
| KEGG Pathway | Ras signaling pathway | |||
| Rap1 signaling pathway | ||||
| Cytokine-cytokine receptor interaction | ||||
| PI3K-Akt signaling pathway | ||||
| Focal adhesion | ||||
| NetPath Pathway | TNFalpha Signaling Pathway | |||
| Pathway Interaction Database | VEGF and VEGFR signaling network | |||
| VEGFR3 signaling in lymphatic endothelium | ||||
| Reactome | VEGF binds to VEGFR leading to receptor dimerization | |||
| WikiPathways | Signaling by VEGF | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01288989) A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Bevacizumab and breast cancer: what does the future hold . Future Oncol. 2012 April; 8(4): 403-414. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.